2020
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Woldu S, Ng C, Loo R, Slezak J, Jacobsen S, Tan W, Kelly J, Lough T, Darling D, van Kessel K, de Jong J, van Criekinge W, Shariat S, Hiar A, Brown S, Boorjian S, Barocas D, Svatek R, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. Journal Of Urology 2020, 205: 1387-1392. PMID: 33356483, DOI: 10.1097/ju.0000000000001550.Peer-Reviewed Original ResearchConceptsIncidence of bladder cancerBladder cancerHigh-risk groupRisk groupsRisk strataCancer incidenceDegree of hematuriaHigh-risk patientsRisk stratification systemAmerican Urological AssociationEvaluation of patientsMultinational cohort studyRisk-stratified approachBladder cancer incidenceHematuria patientsClinically meaningful categoriesGross hematuriaUrologic evaluationIntermediate riskProspective registryRisk patientsContemporary patientsSmoking historyUrological AssociationHematuria
2019
Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Tan W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J, Khetrapal P, Baker H, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Watson D, Knight H, Maher S, Rane A, Pathmanathan B, Harmathova A, Hellawell G, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann A, Cook J, Cornwell M, Mills R, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Gupwell K, Whiteley S, Brown A, McGrath J, Lunt N, Hill P, Sinclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Davies M, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, Speed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Rees A, Williams S, Dukes S, Goffe A, Dawson L, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Payne D, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K, Sarpong R, Brew‐Graves C, Williams N. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal Of Internal Medicine 2019, 285: 436-445. PMID: 30521125, PMCID: PMC6446724, DOI: 10.1111/joim.12868.Peer-Reviewed Original ResearchConceptsCancer risk scoreNational Institute for Health and Clinical Excellence guidelinesRisk scoreInvestigation of haematuriaPhysician decision-makingAge-specific thresholdsValidation cohortExcellence guidelinesUK hospitalsAmerican Urological Association guidelinesNational guidelinesImprove patientNo significant overfittingImprove patient selectionUpper tract cancerLack of consensusAssociation guidelinesSmoking historySwiss patientsCohortPatient ageDevelopment cohortPatient selectionGuidelinesHaematuria
2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Kibel A, Chang S. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal Of Urology 2018, 37: 2059-2065. PMID: 30446799, DOI: 10.1007/s00345-018-2550-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedHealth Care CostsHumansMaleNeoplasm InvasivenessRisk AssessmentUrinary Bladder NeoplasmsConceptsBladder cancerProgression to muscle-invasive diseaseNon-muscle-invasive bladder cancerHigh-risk disease patientsEORTC risk calculatorHigh-risk NMIBCManagement of NMIBCMuscle-invasive diseaseLow-risk tumorsBiologically heterogeneous diseaseHigh-risk diseaseSurveillance of patientsMethodsA Markov modelLong-term surveillanceHigh-risk groupPatient risk groupsOverall cost of careCost of surveillanceCost of careIntermediate-riskSurveillance cystoscopyExpensive malignanciesIndex patientPatient basisNMIBCBOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyCan Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Feber A, Kelly J, Collaborators D. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? Journal Of Urology 2018, 200: 973-980. PMID: 29702097, PMCID: PMC6179963, DOI: 10.1016/j.juro.2018.04.065.Peer-Reviewed Original ResearchConceptsUpper tract urothelial cancerComputerized tomography urogramBladder ultrasoundIncidence of bladderUrinary tract cancerMicroscopic hematuriaUrothelial cancerBladder cancerIncidence of upper tract urothelial cancerIncidence of urinary tract cancerRenal calculiPredictive valueUpper tract imagingDetecting bladder cancerNegative predictive valueDetect renal cancerDiagnosed bladder cancerPositive predictive valueSuspected renal calculiHematuria casesMacroscopic hematuriaRenal cancerHematuriaInvestigated patientsCystoscopyWho Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients
Tan W, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly J, collaborators O. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European Urology 2018, 74: 10-14. PMID: 29653885, DOI: 10.1016/j.eururo.2018.03.008.Peer-Reviewed Original ResearchConceptsUrinary tract cancerIncidence of urinary tract cancerInvestigation of haematuriaRisk of urinary tract cancerClinically significant cancerDiagnosis of urinary tract cancerHigh-risk cancerProspective observational studyIncidence of cancerSignificant cancerAge thresholdBladder cancerSmoking historyVisible bloodOlder patientsHaematuriaMale genderConsensus recommendationsPatientsObservational studyCancerPatient preferencesCancer diagnosisLack of consensusAge